Skip to main content
. 2024 Oct 30;16(21):3660. doi: 10.3390/cancers16213660

Figure 7.

Figure 7

Effects of combined EZH2 inhibitor and ferroptosis inducer treatment in MM. (A–C) Evaluation of combinatorial treatment effects on melanoma organoid models. (A) Schematic representation of the experimental design for combinatorial treatment with MS8815 and erastin on melanoma organoid models. (B) Representative images of melanoma organoids treated with DMSO (vehicle control), MS8815, erastin, and a combination of MS8815 and erastin, showing morphological changes (n = 3). Scale bar: 100 µm. (C) Quantification of cellular ATP levels as a measure of cell viability post-treatment (*** p < 0.001 compared to vehicle control). (D–F) Effects of combined MS8815 and erastin on tumor growth in a MM PDX model. (D) Tumor volume was measured over an 18-day period. (E) Tumors were weighed and plotted (n = 5). Data were expressed as mean ± SEM. * p < 0.05, *** p < 0.001. (F) Representative images from H&E and immunohistochemical staining of Ki-67 protein expression. Scale bars: 100 μm.